Canine hemangiosarcoma is an incurable tumor of cells that line blood vessels. This type of sarcoma is difficult to treat because of its aggressive behavior and rapid progression after diagnosis.
Although dogs of any age and breed are susceptible to hemangiosarcoma, it occurs more commonly in dogs beyond middle age, and in breeds such as Golden Retrievers, German Shepherd Dogs, Portuguese Water Dogs, and Skye Terriers, among others. Hemangiosarcoma develops slowly and is essentially painless; so clinical signs are usually not evident until the advanced stages when the tumors are resistant to most treatments. Fewer than fifty percent of dogs treated with surgery and intensive chemotherapy survive more than six months.
Exciting development in the fight against canine cancer
February 2017 The University of Minnesota shared exciting news regarding a canine oncology study facilitated at their Veterinary Medical Center. The breakthrough study tested a new UMN-developed drug and resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA). The drug, called eBAT, was invented by study senior author Daniel Vallera, Ph.D., professor at the University of Minnesota Medical School and Masonic Cancer Center.
eBAT was tested on 23 dogs of various breeds, both large and small, with HSA of the spleen. The drug treatment improved the 6-month survival rate to approximately 70%. Furthermore, five of the 23 dogs that received eBAT treatment lived more than 450 days.
“This is likely the most significant advance in the treatment of canine HSA in the last three decades,” said study co-author Jaime Modiano, V.M.D., Ph.D. professor in the University of Minnesota College of Veterinary Medicine and member of the Masonic Cancer Center, University of Minnesota.
Below is a link to the press release with further details.